Drugs / TVAV-008
last change Dec 2025 re-read 2 minutes ago

TVAV-008

Developed for
chronic hepatitis B virus infection
Investigated by
Grand Theravac Life Sciences (Nanjing) Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07282249 Dec 2025 → Apr 2027 expected chronic hepatitis B virus infection Grand Theravac Life Sciences (Nanjing) Co., Ltd. Not yet recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TVAV-008 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07282249